How do we do it?

Our four interlinked research domains will create a new investment framework to capture the wider costs and benefits of infectious diseases interventions.

Population-wide impacts

Models that incorporate population-immunity and population heterogeneity in transmission will be used to fully capture the health impacts.

Equity impacts

Novel approaches will be used to incorporate the distributional effects of interventions into empirical economic models.

Community and consumer preferences

Models that incorporate population-immunity and population heterogeneity in transmission will be used to fully capture the health impacts.

Economy-wide impacts

Multi-country multi-sector general equilibrium models will be used to assess the macroeconomic impact of potential policies.

Figure 1

Foundational studies

Our CRE will achieve collaborative gain by measuring and comparing the impact of multiple interventions across different infectious diseases. Guided by our Impact framework, we will achieve a more synergised approach to the way priority areas for investment are identified, which would not otherwise exist in the individual trials/cohort studies. Fundamental to this approach are 10 large-scale trials, cohorts, and observational studies that members of our team currently lead in Australia and the Asia-Pacific. STRIDE’s new health economics research organised under the 4 Domains (Fig 1), will be embedded into these studies (referred to as ‘foundation studies’). These studies evaluate one or more interventions addressing major global public health challenges in infectious diseases

	Disease	Title and CRE investigators	Setting
1	Antibiotic resistance*	Improving antibiotic use by community pharmacies (PINTAR) Wiseman, Kaldor, Guy	Indonesia (community)
2	Antibiotic resistance	Multifaceted antibiotic stewardship intervention for gonorrhoea (GRAND2) Guy, Kaldor	Australia (sexual health services)
3	HIV/syphilis	Quality improvement intervention to strengthen testing and treatment for syphilis and HIV in pregnancy (MENJAGA) Wiseman, Guy, Kaldor	Indonesia (Antenatal clinics)
4	HIV and other sexually transmitted infections	Scaling up infectious disease point-of-care testing for Indigenous people Guy, Kaldor, Wiseman, Canfell, Gray, Vallely, Shih, Cheng	Australia (primary care)
5	Covid-19*	Impact of COVID-19 pandemic on TB and HIV continuums of care (DOMINO) Wiseman, Kaldor, Thabrany	Indonesia (Primary care)
6	Covid-19*	Point of care testing among disadvantaged and vulnerable populations Guy, Kaldor, Wiseman	Australia (remote primary care)
7	TB	Ending Tuberculosis. Community-wide universal testing and treatment for latent TB infection in high prevalence settings (ACT5) Marks	Vietnam
8	TB	Community-wide active case finding for tuberculosis (ACT3) Marks	Vietnam
9	HPV and cervical cancer elimination	Primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women in Australia (COMPASS) Canfell	Australia
10	HPV and cervical cancer elimination	HPV-based testing and treatment for the elimination of cervical cancer in Papua New Guinea Vallely, Kaldor, Canfell, Guy
Note: All projects are randomised controlled trials except those marked * which indicates quasi-experimental design.